Literature DB >> 11431733

Restoration of cerebral blood flow autoregulation and reactivity to carbon dioxide in acute liver failure by moderate hypothermia.

R Jalan1, S W Olde Damink, N E Deutz, P C Hayes, A Lee.   

Abstract

In patients with acute liver failure (ALF) and uncontrolled intracranial hypertension, moderate hypothermia (32 degrees C) reduces intracranial pressure (ICP) and cerebral blood flow (CBF), and can be used as a bridge to liver transplantation. The purpose of this study was to test the hypothesis that moderate hypothermia reduced ICP by restoring CBF autoregulation. Nine patients with uncontrolled intracranial hypertension and ALF who fulfilled the criteria for poor prognosis were studied. CBF autoregulation and reactivity to carbon dioxide were evaluated before and 4 hours after cooling (32 degrees C). Significant reductions were observed in the ICP (median, 46 [range, 27-54] mm Hg to 19 [15-22] mm Hg; P <.01) and CBF (median, 111 [69-134] to 56 [38-67] mL/100 g/min; P <.05). The defective CBF autoregulation and the absence of reactivity to carbon dioxide that was observed in all patients was restored with cooling. The results of our study suggest that the improvement in ICP observed with hypothermia may be the result of its effects on CBF autoregulation and provides a tool to explore the mechanisms associated with the deranged CBF autoregulation in ALF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11431733     DOI: 10.1053/jhep.2001.25386

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  24 in total

1.  Continuous cerebral blood flow autoregulation monitoring in patients undergoing liver transplantation.

Authors:  Yueying Zheng; April J Villamayor; William Merritt; Aliaksei Pustavoitau; Asad Latif; Ramola Bhambhani; Steve Frank; Ahmet Gurakar; Andrew Singer; Andrew Cameron; Robert D Stevens; Charles W Hogue
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

2.  Effects of porta-systemic shunting and ammonia infusion on cerebral blood flow autoregulation in the rat.

Authors:  Thomas Dethloff; Gitte Moos Knudsen; Bent Adel Hansen; Fin Stolze Larsen
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

3.  Brain preservation during orthotopic liver transplantation in a patient with acute liver failure and severe elevation of intracranial pressure.

Authors:  Alexandru Gottlieb; Kathrine R DeBoer
Journal:  J Gastrointest Surg       Date:  2005 Sep-Oct       Impact factor: 3.452

Review 4.  Therapy of intracranial hypertension in patients with fulminant hepatic failure.

Authors:  Murugan Raghavan; Paul E Marik
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

5.  Near-infrared spectroscopy for evaluation of cerebral autoregulation during orthotopic liver transplantation.

Authors:  Peter Nissen; Heidi Pacino; Hans J Frederiksen; Srdan Novovic; Niels H Secher
Journal:  Neurocrit Care       Date:  2009-05-07       Impact factor: 3.210

6.  Fulminant hepatic failure: when the hepatologist meets the neurointensivist.

Authors:  William M Lee; Eelco F M Wijdicks
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

Review 7.  Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation.

Authors:  Dominic R Aldridge; Edward J Tranah; Debbie L Shawcross
Journal:  J Clin Exp Hepatol       Date:  2014-06-30

Review 8.  Management in acute liver failure.

Authors:  Subrat K Acharya
Journal:  J Clin Exp Hepatol       Date:  2014-12-03

Review 9.  Neurological management of fulminant hepatic failure.

Authors:  Jennifer A Frontera; Thomas Kalb
Journal:  Neurocrit Care       Date:  2011-04       Impact factor: 3.210

Review 10.  Therapeutic hypothermia for acute liver failure: toward a randomized, controlled trial in patients with advanced hepatic encephalopathy.

Authors:  R Todd Stravitz; William M Lee; Andreas H Kramer; David J Kramer; Linda Hynan; Andres T Blei
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.